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Many of the recently approved therapies in non–small-cell lung cancer (NSCLC) are preferentially active against 
nonsquamous NSCLC, so development of effective targeted 
therapies in squamous cell histology tumors is a promising 
area of investigation. Discoidin domain receptor 2 (DDR2) 
mutations occur infrequently in squamous NSCLC but seem 
to be more prevalent than in adenocarcinoma. The fibroblast 
growth factor receptor (FGFR) signaling pathway, compris-
ing 22 FGF ligands and four FGF receptors, is also frequently 
amplified or mutated in squamous NSCLC. Small-molecule 
drugs that target these molecular alterations in NSCLC are 
discussed here.
SUMMARY OF PRESENTATIONS
FGFR1 Amplification
Dr. Murry Wynes discussed FGFR1 gene amplifica-
tion in NSCLC. FGFR1 is selectively amplified in squamous 
cell histology NSCLC. On single nucleotide polymorphism 
(SNP) arrays, FGFR1 amplification was noted in 10% to 21% 
of squamous cell tumor samples and in 1% to 3% of non-
squamous lung tumors. Fluorescence in situ hybridization on 
squamous cell tumor samples showed FGFR1 amplification 
in approximately 22% of patients.1,2 FGFR tyrosine kinase 
inhibitors (TKIs) have activity in FGFR1-amplified cell lines.3 
FGFR1 expression may be a prognostic marker in squamous 
NSCLC.4 SNP analysis, gene copy number by fluorescence or 
silver in situ hybridization, protein expression by immunohis-
tochemistry, and mRNA expression by reverse transcriptase-
polymerase chain reaction are all being explored as potential 
biomarkers of FGFR1. FGFR2 mutations have also been iden-
tified in up to 5% of squamous histology lung tumors.5
AZD4547
Dr. Edward Kim presented AZD4547, an oral tyro-
sine kinase inhibitor of FGFR1–3. In cell lines harboring an 
FGFR1 gene fusion, AZD4547 inhibits downstream FGFR 
signaling; cells with FGFR2 gene amplification and FGFR3 
translocation plus mutation also demonstrate sensitivity to 
AZD4547. In an FGFR2-amplified gastric cancer xenograft 
mouse model, AZD4547 inhibits tumor growth. The clini-
cal program includes phase I dose-escalation studies in solid 
tumors (NCT00979134) and phase II studies in FGFR1-
amplified breast cancer (NCT01202591) as well as in FGFR2-
amplified gastric cancer (NCT01457846).
BGJ398
Dr. Lecia Sequist presented the pan-FGFR kinase inhibi-
tor BGJ398, which is most potent against FGFR1–3. It has 
antitumor activity in an FGFR3-amplified bladder cancer xeno-
graft model.6 A multi-institution phase I dose-escalation study 
is currently recruiting in solid tumors with FGFR1 and FGFR2 
amplification as well as FGFR3 mutations (NCT01004224).
Dovitinib
Dr. Joel Neal presented dovitinib (TKI 258), a small-
molecule tyrosine kinase inhibitor with activity against both 
vascular endothelial growth factor receptor (VEGFR) and 
FGFR1–3. Multiple clinical trials are ongoing, including 
phase III trials in renal cell carcinoma (NCT01223027). As 
FGFR signaling may contribute to acquired erlotinib resis-
tance,7 a phase I trial combining erlotinib and dovitinib is 
open for patients with NSCLC (NCT01515969).
Ponatinib
Dr. Ross Camidge presented ponatinib, a multitargeted 
tyrosine kinase inhibitor designed to overcome the T315I 
resistance mutation in BCR-ABL in chronic myelogenous 
leukemia. In preclinical models, it also has notable activity 
against FGFR1–4 as well as RET, VEGFR2, platelet derived 
growth factor receptor, and other tyrosine kinases. Several 
development strategies are being considered in NSCLC 
including patients with tumors having FGFR gene amplifi-
cation, FGF pathway signatures, and also other non-FGFR 
targets of ponatinib.
Discoidin Domain Receptor 2 
Dr. Ming Tsao discussed DDR2 mutations in squamous 
NSCLC and Dr. Faye Johnson elaborated on the potential role 
for dasatinib in targeting this mutation. DDR2 is a receptor 
tyrosine kinase that binds collagen and promotes cell migra-
tion, survival, and proliferation when activated.8,9 Sanger 
sequencing of the tyrosine kinome identified DDR2 muta-
tions in approximately 4% of the squamous NSCLC tumors 
and cell lines tested.10 Twelve different DDR2 mutations have 
been identified thus far.
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Dasatinib
Dasatinib is a promiscuous tyrosine kinase inhibitor best 
known for its activity against BCR-ABL in chronic myelog-
enous leukemia and c-KIT in gastrointestinal stromal tumors. 
It also seems to have activity against DDR2, and DDR2-driven 
cell lines are sensitive to inhibition with dasatinib. In a com-
pleted phase II trial, dasatinib has little activity in an unselected 
population with NSCLC.11 However, in a phase I trial with erlo-
tinib and dasatinib, a patient with a prolonged partial response 
was later identified as having a DDR2 mutation.
On the basis of preclinical and early clinical evidence of 
activity of dasatinib in patients harboring DDR2 mutations, an 
ongoing phase II trial (NCT01491633) is looking at dasatinib in 
squamous histology NSCLC patients whose tumors with DDR2.
FUTURE DIRECTIONS
FGFR and DDR2 are potential driver genetic alterations 
observed in NSCLC of squamous histology. Ongoing early-
phase clinical trials of novel and established drugs are testing 
whether these genetic alterations qualify as actionable. On the 
basis of promising preclinical data, we hope to see clinical 
benefit from targeting these pathways in subsets of patients 
with NSCLC selected by histological or molecular features.
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